Difference between revisions of "Asciminib (Scemblix)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allosteric-bcr-abl-tyrosine-kinase-inhibitor-abl001 NCI Drug Dictionary]: An...") |
m |
||
| Line 3: | Line 3: | ||
==Preliminary data== | ==Preliminary data== | ||
| − | ===[[Chronic | + | ===[[Chronic myelogenous leukemia]]=== |
# '''CABL001X2101:''' Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. [https://www.nejm.org/doi/full/10.1056/NEJMoa1902328 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/31826340 PubMed] | # '''CABL001X2101:''' Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. [https://www.nejm.org/doi/full/10.1056/NEJMoa1902328 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/31826340 PubMed] | ||
| Line 12: | Line 12: | ||
[[Category:Bcr-Abl inhibitors]] | [[Category:Bcr-Abl inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 18:46, 26 January 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, asciminib binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies.
Preliminary data
Chronic myelogenous leukemia
- CABL001X2101: Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. link to original article PubMed